Theriva Biologics, Inc. Common Stock TOVX 深 滬
已收盤 08-22 16:00:00 美东时间
0.4285
-0.001
-0.23%
華盛通- 最 高0.436
- 今 開0.4208
- 成交量 21.01万股
- 最 低 0.4207
- 昨 收 0.4295
- 總市值 388.19万
- 52周最高 5.67
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.3654
- 委 比 0.00%
- 總股本 905.92万
- 歷史最高 37800.00
- 量 比 0.06
- 振 幅 3.56%
- 歷史最低 0.3654
- 每 手 1
- 風險率 3.74%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Theriva Biologics Q2 EPS $(1.93) Misses $(1.08) Estimate
Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(1.93) per share which missed the analyst consensus estimate of $(1.08) by 78.7 percent. This is a 82 percent increase over losses of $(10.72) per share from
08-11 20:14
Theriva Biologics GAAP EPS of -$1.93
Theriva Biologics press release (NYSE:TOVX): Q2 GAAP EPS of -$1.93. Cash and cash equivalents of $12.1 million as of June 30, 2025, expected cash runway into Q1 2026 More on Theriva Biologics Seeking ...
08-11 20:03
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 4D Molecular Therapeutics (NASDAQ:FDMT) shares moved upwards by 33.1% ...
08-01 05:07
Theriva Biologics Sets 2025 Shareholder Meeting Date
Theriva Biologics ( ($TOVX) ) just unveiled an announcement. Theriva Biologics,...
06-26 04:41
Theriva Biologics To Present Data From VCN-01 Retinoblastoma Phase 1 Clinical Trial At ASCO 2025; Announces Investigator Meeting To Review Topline Data From VIRAGE Phase 2b Trial Of VCN-01 In Metastatic Pancreatic Cancer
- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical Oncology (ASCO) Annual
05-27 20:08
Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer
Theriva Biologics announced the presentation of final safety and efficacy data from its Phase 1 study evaluating VCN-01 in refractory retinoblastoma patients at the ASCO Annual Meeting on May 31, 2025. The study, conducted at Sant Joan de Déu Barcelona Children’s Hospital, demonstrated positive results, with VCN-01 showing tolerable toxicity and encouraging responses. Theriva senior management will also attend the conference to review topline dat...
05-27 12:00
Theriva Biologics Q1 EPS $(1.55) Up From $(7.53) YoY
Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(1.55) per share. This is a 79.42 percent increase over losses of $(7.53) per share from the same period last year.
05-14 20:44
Healthcare stocks that could be poised for a rebound
Health care (NYSEARCA:XLV) is the most oversold global sector, according to BofA. The sector was down 6.3% from its 200-day moving average in U.S. dollar terms, followed by energy (XLE) and biotechnol...
05-10 00:31
Maxim Group Downgrades Theriva Biologics to Hold
Maxim Group analyst Jason McCarthy downgrades Theriva Biologics (AMEX:TOVX) from Buy to Hold.
05-08 20:11
Theriva Biologics Reports Topline Findings From VIRAGE Phase 2b Trial Of VCN-01 In Pancreatic Cancer
Patients treated with VCN-01 (zabilugene almadenorepvec) plus gemcitabine/nab-paclitaxel standard-of-care (SoC) chemotherapy had increased overall survival, progression free survival, and duration of response compared to
05-07 19:09
